ClinicalTrials.Veeva

Menu

Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales (OPTIC-19)

University of Oxford logo

University of Oxford

Status

Active, not recruiting

Conditions

Pulmonary Embolism
Renal Failure
Stroke
Critical Illness
Deep Vein Thrombosis
Covid19
Myocardial Infarction
Heart Failure

Treatments

Other: Not applicable as observational study

Study type

Observational

Funder types

Other

Identifiers

NCT04838106
21/SC/0021 (Other Identifier)
PID15456
21/CAG/0017 (Other Identifier)

Details and patient eligibility

About

This retrospective cohort study aims to characterise outcomes for patients treated on an intensive care unit (ICU) with COVID-19 in England and Wales, one year after discharge from hospital. Outcomes will be compared with patients admitted as an emergency to an ICU for other conditions. The study will use existing national audit data linked to routine healthcare datasets.

Full description

Across England and Wales, over 10,000 patients have been treated for severe coronavirus disease 2019 (COVID-19) on an intensive care unit. Around 60% survived to leave hospital. It is unknown how survivors' severe COVID-19 infection, or the treatment they received on the intensive care unit, will affect their long-term health. Understanding what happens to these patients can help ensure they receive suitable care from their General Practitioner (GP) and other National Health Service (NHS) services after they leave hospital.

This study will follow up survivors for 1 year after discharge from hospital. The investigators will use data collected by the Intensive Care National Audit and Research Centre (ICNARC) to identify patients who were treated on an ICU for COVID-19. The investigators will then use NHS data to see whether these patients were readmitted to hospital and why. Information from the Office of National Statistics will identify whether patients died. By linking different sources of patient data, the investigators will estimate the health risks faced by survivors of severe COVID-19. These risks will be compared to those in patients treated on an ICU for other conditions.

Enrollment

319,600 estimated patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 16 years or over
  • Admitted to an adult, general ICU in England or Wales as an emergency (unplanned)
  • Admitted to ICU for either: a) confirmed COVID-19 between 1st January to 1st July 2020 or b) without confirmed COVID-19 between 1st July 2016 and 1st July 2020-

Exclusion criteria

  • Patients who died in hospital after treatment on an ICU

Trial design

319,600 participants in 2 patient groups

Covid19
Description:
Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency with confirmed COVID-19 between 1st January to 1st July 2020.
Treatment:
Other: Not applicable as observational study
Non Covid19
Description:
Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency without confirmed COVID-19 between 1st July 2016 and 1st July 2020.
Treatment:
Other: Not applicable as observational study

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems